One of the most dangerous forms of cancer isnon-small cell lung cancer, which is often fatal due to the fact that the tools for diagnosing the disease at an early stage are often not very effective. However, according to journalists from the EurekAlert publication, a group of US researchers managed to develop a method for identifying this form of cancer using a new method based on the analysis of exosomes isolated from blood and saliva.
Diagnostics made by technologyEFIRM (electric field-induced release and measurement) is a method based on extracting exosomes (microscopic extracellular bubbles containing various structures) from biological fluids and analyzing their RNA and proteins. This approach is highly sensitive and extremely effective for detecting growth factor receptor mutations associated with the development of non-small cell lung cancer. According to the doctor of medical sciences and one of the authors, Charles Strom, who works at UCLA (University of California in Los Angeles),
“The revolutionary EFIRM technology is a directthe development of a non-invasive fluid biopsy. Her potential is enormous. Tens of thousands of lives around the world can be saved by detecting lung cancer in its early stages. EFIRM technology can also be used to monitor treatment and detect relapse in patients with already diagnosed lung cancer. ”
Scientists to determine whether a disease is presenttry to detect the presence of two mutations - p.L858r and Exon 19del. They are easily detected in the blood of patients with the late stage of the oncological process, and therefore must be present in the initial stages. EFIRM allows you to do this. During the study, scientists collected plasma samples from 248 patients with a pathological process in the lungs. Of these, 44 were diagnosed with a process of 1 or 2 stages (23 with benign pulmonary nodes, confirmed by biopsy, and 21 with cancer of unknown etiology). The remaining participants in the experiment did not identify the cancer, but the most interesting thing lies elsewhere: of those people who had been diagnosed with non-small cell lung cancer (12 of 21 such people), in 90% of cases (11 volunteers) could detect p.L858r and Exon 19del, pointing out the development of cancer.
“We are satisfied with the work of the EFIRM platform and thethat it can detect cancer in patients whose tumors were still small enough to provide them with skilled surgical care. We are now working to increase the number of mutations analyzed and automate the process to increase sensitivity and facilitate screening. ”
What do you think about the new way? Express in our chat in Telegram.